Semaphorin 3A contributes to sepsis‑induced immunosuppression by impairing CD4
Animals
Antioxidants
/ administration & dosage
CD4-Positive T-Lymphocytes
/ immunology
Catechin
/ administration & dosage
Cells, Cultured
Clonal Anergy
/ immunology
Humans
Immune Tolerance
/ immunology
Lipopolysaccharides
/ immunology
Male
Mice, Inbred C57BL
Multiple Organ Failure
/ immunology
NF-kappa B
/ immunology
Semaphorin-3A
/ antagonists & inhibitors
Sepsis
/ immunology
Signal Transduction
/ drug effects
sepsis
immunosuppression
multiple organ dysfunction syndromes
CD4+ Tcells
semaphorin 3A
Journal
Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
04
08
2020
accepted:
25
01
2021
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
18
5
2021
Statut:
ppublish
Résumé
Semaphorin 3A (Sema3A), a member of the Sema family of proteins, appears to serve an important role in sepsis and sepsis‑induced immunosuppression and has been regarded as a crucial regulator involved in cellular immune response. However, the role of Sema3A in CD4
Identifiants
pubmed: 33649856
doi: 10.3892/mmr.2021.11941
pii: 302
pmc: PMC7930987
doi:
pii:
Substances chimiques
Antioxidants
0
Lipopolysaccharides
0
NF-kappa B
0
Semaphorin-3A
0
Catechin
8R1V1STN48
epigallocatechin gallate
BQM438CTEL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
JAMA. 2017 Jan 17;317(3):290-300
pubmed: 28114553
Sci Rep. 2015 Nov 18;5:16725
pubmed: 26577833
Ann Neurol. 2011 Feb;69(2):341-51
pubmed: 21387379
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Mol Cell Neurosci. 2006 Jan;31(1):52-69
pubmed: 16230022
Eur J Immunol. 2006 Jul;36(7):1782-93
pubmed: 16791896
J Immunol. 2010 Nov 15;185(10):6373-83
pubmed: 20937848
Nature. 2007 Mar 29;446(7135):552-6
pubmed: 17322906
Intensive Care Med. 2018 Jul;44(7):1071-1080
pubmed: 29846748
Nat Immunol. 2000 Dec;1(6):533-40
pubmed: 11101877
N Engl J Med. 2015 Apr 23;372(17):1629-38
pubmed: 25776936
J Exp Med. 2010 Dec 20;207(13):2943-57
pubmed: 21098092
JAMA. 2011 Dec 21;306(23):2594-605
pubmed: 22187279
J Immunol. 2004 May 15;172(10):6065-73
pubmed: 15128790
J Mol Med (Berl). 2018 Jul;96(7):713-724
pubmed: 29909462
Crit Care. 2011 Jul 28;15(4):R183
pubmed: 21798063
J Neurosci. 2006 Mar 15;26(11):2971-80
pubmed: 16540575
Scand J Immunol. 1996 Jul;44(1):85-8
pubmed: 8693296
Crit Care. 2014 Aug 01;18(4):R163
pubmed: 25084831
Inflammopharmacology. 2018 Jun;26(3):655-665
pubmed: 29696565
J Exp Med. 2007 Jun 11;204(6):1463-74
pubmed: 17548519
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
Int Immunol. 2015 Sep;27(9):459-66
pubmed: 25855660
Intensive Care Med. 2020 Jun;46(6):1246-1248
pubmed: 32270211
Crit Care Med. 2020 Mar;48(3):e209-e218
pubmed: 31804299
Blood. 2006 Apr 15;107(8):3321-9
pubmed: 16380453
Science. 2010 Sep 24;329(5999):1667-71
pubmed: 20929851
Nutr Clin Pract. 2017 Jun;32(3):296-308
pubmed: 28537517
Nat Immunol. 2020 Jul;21(7):708-709
pubmed: 32577010
Nat Immunol. 2002 May;3(5):477-82
pubmed: 11953749
J Neurosci. 2019 Nov 6;39(45):8885-8899
pubmed: 31537704
J Neuropathol Exp Neurol. 2016 Feb 25;75(4):326-333
pubmed: 26921371